Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: Review and meta-analysis

Journal of Clinical Psychiatry

Volumn 71, Issue 4, 2010, Pages 411-418

  Dlabač de Lange, Jozarni J ^a   Knegtering, Rikus ^a   Aleman, André ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; FUNCTIONAL LATERALITY; HUMANS; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 77951029973     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08r04808yel     Document Type: Article

References (70)

1. Buchanan RW, Gold JM. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol. 1996;11(suppl 2):3-11.
2. Gasquet I, Haro JM, Novick D, et al. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol. 2005;20(4):199-205. (Pubitemid 40896374)
3. Kurtz MM, Moberg PJ, Ragland JD, et al. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull. 2005;31(1)167-174.
4. Sergi MJ, Kern RS, Mintz J, et al. Learning potential and the prediction of work skill acquisition in schizophrenia. Schizophr Bull. 2005;31(1):67-72. (Pubitemid 41214357)
5. Harvey PD, McClure MM. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs. 2006;66(11):1465-1473. (Pubitemid 44246604)
6. Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006;88(1-3):5-25. (Pubitemid 44693240)
7. Barch DM, Carter CS, Braver TS, et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry. 2001;58(3):280-288. (Pubitemid 32209682)
8. Perlstein WM, Carter CS, Noll DC, et al. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry. 2001;158(7):1105-1113. (Pubitemid 32623115)
9. Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry. 2002;159(2):227-237.
10. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004;161(3):398-413. (Pubitemid 38326093)
11. Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex. 2007;17(suppl 1):i171-i181.
12. Weinberger DR, Berman KF. Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci. 1996;351(1346):1495- 1503.
13. Wolkin A, Sanfilipo M, Wolf AP, et al. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry. 1992;49(12):959-965.
14. Hill K, Mann L, Laws KR, et al. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004;110(4):243-256. (Pubitemid 39278982)
15. Peinemann A, Reimer B, Loer C, et al. Long-lasting increase in corticospinal excitability after 1800 pulses of subthreshold 5 Hz repetitive TMS to the primary motor cortex. Clin Neurophysiol. 2004;115(7):1519-1526.
16. Shajahan PM, Glabus MF, Steele JD, et al. Left dorso-lateral repetitive transcranial magnetic stimulation affects cortical excitability and functional connectivity, but does not impair cognition in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5):945-954.
17. Goldman-Rakic PS. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry. 1999;46(5):650-661.
18. Goldman-Rakic PS, Muly EC III, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31(2-3):295-301.
19. Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004;174(1):3-16. (Pubitemid 38925085)
20. Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl). 2004;174(1):111-125.
21. Pogarell O, Koch W, Popperl G, et al. Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine. Psychiatry Res. 2007;156(3):251-255. (Pubitemid 350116554)
22. Pogarell O, Koch W, Popperl G, et al. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study. J Psychiatr Res. 2006;40(4):307-314. (Pubitemid 43668986)
23. Strafella AP, Paus T, Barrett J, et al. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. 2001;21(15):RC157.
24. Strafella AP, Paus T, Fraraccio M, et al. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain. 2003;126(Pt 12):2609-2615. (Pubitemid 37463080)
25. Funamizu H, Ogiue-Ikeda M, Mukai H, et al. Acute repetitive transcranial magnetic stimulation reactivates dopaminergic system in lesion rats. Neurosci Lett. 2005;383(1-2):77-81. (Pubitemid 40779959)
26. Kanno M, Matsumoto M, Togashi H, et al. Effects of acute repetitive transcranial magnetic stimulation on dopamine release in the rat dorsolateral striatum. J Neurol Sci. 2004;217(1):73-81. (Pubitemid 37532720)
27. Zangen A, Hyodo K. Transcranial magnetic stimulation induces increases in extracellular levels of dopamine and glutamate in the nucleus accumbens. Neuroreport. 2002;13(18):2401-2405. (Pubitemid 36143532)
28. Cohen E, Bernardo M, Masana J, et al. Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. J Neurol Neurosurg Psychiatry. 1999;67(1):129-130. (Pubitemid 29278354)
29. Goyal N, Nizamie SH, Desarkar P. Efficacy of adjuvant high frequency repetitive transcranial magnetic stimulation on negative and positive symptoms of schizophrenia: preliminary results of a double-blind sham-controlled study. J Neuropsychiatry Clin Neurosci. 2007;19(4):464-467. (Pubitemid 350156107)
30. Hajak G, Marienhagen J, Langguth B, et al. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychol Med. 2004;34(7):1157-1163. (Pubitemid 39517146)
31. Langguth B, Eichhammer P, Kharraz A, et al. Repetitive transcranial magnetic stimulation in schizophrenia (preliminary results). Nervenheilkunde. 2003;22:350. (Pubitemid 37022763)
32. Sachdev P, Loo C, Mitchell P, et al. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry Clin Neurosci. 2005;59(3):354-357. (Pubitemid 40897209)
33. Schneider AL, Schneider TL, Stark H. Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study. Brain Stimulation. 2008;1(2):106-111. (Pubitemid 351689965)
34. Prikryl R, Kasparek T, Skotakova S, et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr Res. 2007;95(1-3)151-157. (Pubitemid 47313654)
35. Jandl M, Bittner R, Sack A, et al. Changes in negative symptoms and EEG in schizophrenic patients after repetitive transcranial magnetic stimulation (rTMS): an open-label pilot study. J Neural Transm. 2005;112(7):955-967. (Pubitemid 40869084)
36. Jin Y, Potkin SG, Kemp AS, et al. Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the negative symptoms of schizophrenia. Schizophr Bull. 2005;32(3):556-561. (Pubitemid 43992328)
37. Fitzgerald PB, Herring S, Hoy K, et al. A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation. 2008;1(1)27-32. (Pubitemid 351966358)
38. Holi MM, Eronen M, Toivonen K, et al. Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophr Bull. 2004;30(2):429-434. (Pubitemid 38828546)
39. Klein E, Kolsky Y, Puyerovsky M, et al. Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biol Psychiatry. 1999;46(10):1451-1454. (Pubitemid 29165174)
40. Mogg A, Purvis R, Eranti S, et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr Res. 2007;93(1-3):221-228. (Pubitemid 46817960)
41. Novak T, Horacek J, Mohr P, et al. The double-blind sham-controlled study of high-frequency rTMS (20 Hz) for negative symptoms in schizophrenia: negative results. Neuroendocrinol Lett. 2006;27(1-2):209-213. (Pubitemid 43970795)
42. Wilson DB. Professional Development Course on Meta-Analysis. http://mason.gmu.edu/~dwilsonb/ma.html. Access verified January 4, 2010.
43. Manager R. RevMan [computer program]. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008
44. Stanford AD, Corcoran C, Buloh P, et al. A pilot study of high frequency prefrontal rTMS for the treatment of the negative symptoms of schizophrenia. Biol Psychiatry. 2006;59:77S.
45. Rollnik JD, Huber TJ, Mogk H, et al. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport. 2000;11(18):4013-4015. (Pubitemid 32038795)
46. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
47. Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68(3):416-421. (Pubitemid 46506807)
48. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51-68. (Pubitemid 29023554)
49. Gross M, Nakamura L, Pascual-Leone A, et al. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? a systematic review and meta-analysis comparing the recent vs the earlier rTMS studies. Acta Psychiatr Scand. 2007;116(3):165-173. (Pubitemid 47106664)
50. Cordes J, Arends M, Mobascher A, et al. Potential clinical targets of repetitive transcranial magnetic stimulation treatment in schizophrenia. Neuropsychobiology. 2006;54(2)87-99. (Pubitemid 46143891)
51. Herwig U, Padberg F, Unger J, et al. Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard" coil positioning by neuronavigation. Biol Psychiatry. 2001;50(1)58-61.
52. Fitzgerald PB, Daskalakis ZJ. A review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia. Can J Psychiatry. 2008;53(9):567-576.
53. Burlingame GM, Dunn TW, Chen S, et al. Selection of outcome assessment instruments for inpatients with severe and persistent mental illness. Psychiatr Serv. 2005;56(4):444-451. (Pubitemid 40471587)
54. Norman RM, Malla AK, Cortese L, et al. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophr Res. 1996;19(1):73-85. (Pubitemid 26133215)
55. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788. (Pubitemid 12090301)
56. Thiemann S, Csernansky JG, Berger PA. Rating scales in research: the case of negative symptoms. Psychiatry Res. 1987;20(1):47-55. (Pubitemid 17001582)
57. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2)261-276. (Pubitemid 18039085)
58. Bell M, Milstein R, Beam-Goulet J, et al. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992;180(11):723-728. (Pubitemid 23009554)
59. Eckert SL, Diamond PM, Miller AL, et al. A comparison of instrument sensitivity to negative symptom change. Psychiatry Res. 1996;63(1):67-75.
60. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994;53(1):31-40. (Pubitemid 24266119)
61. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013-1022. (Pubitemid 47216643)
62. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.
63. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196-1204.
64. Ziemann U, Lonnecker S, Steinhoff BJ, et al. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol. 1996;40(3):367-378. (Pubitemid 26304794)
65. Michelucci R, Passarelli D, Riguzzi P, et al. Transcranial magnetic stimulation in partial epilepsy: drug-induced changes of motor excitability. Acta Neurol Scand. 1996;94(1):24-30. (Pubitemid 26276195)
66. Hoffman RE, Boutros NN, Hu S, et al. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet. 2000;355(9209):1073-1075. (Pubitemid 30162814)
67. Loo CK, Taylor JL, Gandevia SC, et al. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some "sham" forms active? Biol Psychiatry. 2000;47(4):325-331.
68. Lisanby SH, Gutman D, Luber B, et al. Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biol Psychiatry. 2001;49(5)460-463. (Pubitemid 32234309)
69. Stanford AD, Sharif Z, Corcoran C, et al. rTMS strategies for the study and treatment of schizophrenia: a review. Int J Neuropsychopharmacol. 2008;11(4):563-576. (Pubitemid 351744807)
70. Hoeft F, Wu DA, Hernandez A, et al. Electronically switchable sham transcranial magnetic stimulation (TMS) system. PLoS One. 2008;3(4)e1923. doi: (Pubitemid 351984122)